ArticleBriefings in bioinformatics2024
Noninvasive fetal genotyping using deep neural networks.
Article in Briefings in bioinformatics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- "First, do no harm" in the digital era: examining the practicality of the European Health Data Space proposal and ethical implications of artificial intelligence: A systematic literature review.BMC medical ethics · 2026Pooled it
- Technological Advances in Molecular Diagnostic Methods for Hereditary Diseases in Preconception and Prenatal Settings.Current issues in molecular biology · 2026Review
- Progress, clinical application and challenges of non-invasive prenatal testing for monogenic diseases.Frontiers in pediatrics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Circulating cell-free DNA (cfDNA) is a powerful diagnostics tool that is widely studied in the context of liquid biopsy in oncology and other fields. In obstetrics, maternal plasma cfDNA have already proven its utility, enabling noninvasive prenatal testing (NIPT), which has become a standard for detecting chromosomal aberrations. However, identification of point mutations responsible for monogenic diseases (NIPT-M) remains limited, even when accounting to fragment specific characteristics (i.e. fragmentomics). While genotyping of individual genomes is performed today using deep learning (DL) algorithms, cfDNA-based noninvasive fetal genotyping is performed only using traditional statistical and machine-learning methods. This study introduces the first DL-based framework for cfDNA based genotyping, heralding a significant stride toward genome-wide NIPT-M. Using unique ultra-deep whole genome sequencing (WGS) data, we were motivated to develop an efficient model, especially when compared with current DL methods for WGS. This facilitates the integration of previously overlooked levels of information, encompassing DNA nucleotides, fragments, mutation regions, samples, and familial traits. Employing this novel approach, we surpass the performance of existing methodologies, successfully detecting three deleterious mutations, and allowing for NIPT-M as early as the 7th week of gestation. Our proposed approach brings genome-wide NIPT for all mutation types closer to clinical feasibility, enabling families and healthcare providers to make well-informed decisions and alleviating the anxieties and uncertainties associated with pregnancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.